Trial Profile
A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2022
Price :
$35
*
At a glance
- Drugs Brexanolone (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Sponsors Sage Therapeutics
- 06 Aug 2021 Status changed from recruiting to discontinued.
- 24 Feb 2021 According to a Sage Therapeutics media release, topline data anticipated in late 2021.
- 15 Jan 2021 Status changed from not yet recruiting to recruiting.